Data as of Q4 2025 (Dec 31, 2025)

TriSalus Life Sciences, Inc.

(TLSI)

Financial Statements · SEC EDGAR XBRL

Revenue
$45.2M
+53.4%
Net Income
-$39.2M
-30.6%
EPS
$-1.84
-40.5%
Gross Margin
84.6%
Op. Income
-$26.9M
+25.5%
FCF
-$18.9M
+54.0%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Research & Development
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$45.2M
$29.4M
$18.5M
$12.4M
-
$45.2M
$29.4M
$18.5M
$12.4M
-
$7.0M
$4.1M
$2.6M
$2.3M
-
$38.2M
$25.3M
$15.9M
$10.1M
-
$15.0M
$17.7M
$29.8M
$21.4M
-
-$26.9M
-$36.2M
-$54.5M
-$36.4M
-$3.0M
-
-
$16K
$1K
-
-$456K
-$312K
-$378K
-$420K
-
-$39.2M
-$30.0M
-$59.4M
-$47.2M
$4.8M
$7K
$6K
$9K
$9K
$0
-$39.2M
-$30.0M
-$59.4M
-$47.2M
$4.8M
$-1.84
$-1.31
$-6.77
$-161.55
-
$-1.84
$-1.31
$-6.77
$-161.55
-
37.9M
25.3M
9.4M
310K
-